Gene Regulation and Therapeutics for Cancer

Surinder K. Batra is a Professor and Chairman of the Department of Biochemistry and Molecular Biology at the University of Nebraska Medical Center. Dr. Batra studies the functions of mucins in the progression of different malignancies. His recent studies demonstrated the molecular mechanism for the progression and metastasis of multiple cancers. His investigations led to developing several targeted therapies for different tumors. Based on his mechanistic and translational studies, different targets entered into Phase I/II trials for various cancers. Moorthy P. Ponnusamy is an Associate Professor of Biochemistry and Molecular Biology at the University of Nebraska Medical Centre. Dr. Ponnusamy’s research background reflects a keen interest in understanding the molecular mechanisms of cancer stem cell-mediated progression and metastatis of pancreatic cancer. His recent studies discovered the specific mechanism for pancreatic cancer stem cell maintenance and its impact on metastatis. He is developing small molecules to target cancer stem cell populations.

Programmed Death 1 Receptor (PD-1)-mediated Immunomodulatory Effects in Pancreatic Cancer. Nuclear Factor Kappa-B: Bridging Inflammation and Cancer. The S100A7/8/9 Proteins: Novel Biomarker and Therapeutic Targets for Solid Tumor Stroma. Nuclear Receptor Coactivators: Mechanism and Therapeutic Targeting In Cancer. Liquid Biopsies for Pancreatic Cancer: A Step Towards Early Detection. Targeting Subgroup-specific Cancer Epitopes for Effective Treatment of Pediatric Medulloblastoma. Aberrant Methylation of UC Promoters in Human Pancreatic Ductal Carcinomas. Receptor Tyrosine Kinase Signaling Pathways as a Goldmine for Targeted Therapy in Head and Neck Cancers. Molecular Drivers in Lung Adenocarcinoma: Therapeutic Implications. Molecular Mediator of Prostate Cancer Progression and Its Implication in Therapy. Therapeutic Options for Prostate Cancer: A Contemporary Update. Regulation and Targeting of MUCINS in Pancreatic Cancer. Targeted Therapy for Cancer Stem Cells.